Press coverage about Pediapharm (NASDAQ:PDP) has been trending somewhat positive on Saturday, Accern Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pediapharm earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.3860447974296 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Pediapharm (NASDAQ:PDP) traded up $0.25 during mid-day trading on Friday, reaching $53.72. 47,507 shares of the company’s stock were exchanged, compared to its average volume of 143,400. Pediapharm has a twelve month low of $42.20 and a twelve month high of $53.78. The company has a market cap of $1,590.00, a P/E ratio of 11.43 and a beta of 0.95.
In other news, Director Benoit Gravel acquired 146,000 shares of Pediapharm stock in a transaction on Tuesday, October 17th. The stock was acquired at an average cost of $0.30 per share, with a total value of $43,800.00.
TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://ledgergazette.com/2018/01/14/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-pediapharm-pdp-share-price.html.
PowerShares DWA Technical Leaders Portfolio (the Fund) is based on the Dorsey Wright Technical Leaders Index (the Index). The Fund seeks investment results that generally correspond to the price and yield of the Index. The Fund will normally invest at least 90% of its total assets in securities that consists of the Index and American Depositary Receipts (ADRs) based on the securities in the Index.
Receive News & Ratings for Pediapharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediapharm and related companies with MarketBeat.com's FREE daily email newsletter.